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Abstract— Computational tools and methods play a vital role in handling and analyzing a large volume of genomic data.  In cancer 
research, in silico methods such as computational algorithm and protein databases are indispensable.  In this paper, we adopted an in 
silico approach to analyze oncogenes that cause renal cancer.  Our objective is to identify and analyze the genes which are over 
expressed in the renal cancer tissues.  The identification of oncogenes for renal cancer could provide directions and insights for 
molecular cancer treatment.   
 




Computational tools and methods have assumed greater 
role in analysing biological and medical data.  These data 
which are generated in the laboratory are enormously large 
in volume.  Genetic sequences, for example, could possess a 
length of millions of neucleotides.  To make genetic data 
useful for biological research and medical therapy, it is 
always necessary to use computational tools to analyse and 
organize them. 
In this paper, we took an in silico approach to analyze 
oncogenes that cause renal cancer.  It was reported that 
nearly 50% of renal cancer patients have eventually suffered 
from degenerated conditions in which metastases have 
developed [1].  This malignant condition has contributed to 
high mortal rate in the patients.  It was estimated that 
approximately 78,000 deaths among renal cancer patients 
have been recorded [2].  The identification of oncogenes 
could provide directions and insights for molecular cancer 
therapy.        
We made use of Expressed Sequenced Tags (ESTs) to 
generate the data for both normal and cancerous renal cell 
line.  ESTs were fragments of cDNA that were widely used 
by bioinformaticians and computer scientists in gene 
sequencing and analysis. Our objective is to identify and 
analyze the genes which are over expressed in the renal 
cancer tissues.  Our computational analysis may improve 
the understanding of the genes which play a regulatory role 
in renal carcinogenesis.  Furthermore, computational 
analysis of protein expression of the oncogenes will reveal 
the relation between the renal cancer and genetic content at 
molecular level. 
II. METHODS 
We used Expressed Sequence Tags (EST) to analyze both 
normal and cancerous renal tissue.  All EST libraries were 
selected with a minimum of 2000 sequences per library.  
We used cell line as the tissue preparation type for both 
normal and cancerous tissue histology.  We set the library 
protocol to non-normalized in order to maximize the 
number of candidate genes.  
We specified the minimum gene expression factor as 20.  
It implies that the resultant genes are expected to have over-
expressed for at least 20 folds.  This high threshold enables 
us to exclude the irrelevant genes from our analysis. 
The false discovery rate was set to 0.001, which is a 
value considerably sensitive to the significant expression of 
genes.  With all 46 chromosomes being included, we 
obtained 8 EST libraries, as shown in Table 1. 
 
TABLE I 
EST LIBRARIES IMPLICATED IN RENAL CANCER CELL LINE 
 











   Based on the EST libraries as shown in Table 1, we 
generated the over-expressed genes which are implicated in 
renal cancer.  The gene ontology was identified.  From the 
obtained mRNA sequences, we identified the protein 
sequences for each oncogene which is correlated to renal 
carcinogenesis. 
III. RESULTS AND DISCUSSIONS 
There were 3 EST libraries with a total of 28564 
sequences implicated as cancer cells; whereas we obtained 5 
EST libraries with a total of 37421 sequences as normal 
cells.  After excluding the genes which have invalid 
sequence odds ratio (OR), we obtained 17 candidate genes 
for renal cancer, as shown in Table 2.    
 
TABLE 2 
CANDIDATE GENES FOR RENAL CANCER 
Genes Sequences OR Q 
Cancer Normal  
IGFBP3 121 2 79.59 2.79e-38 
LMNA 43 1 56.42 2.91e-12 
TGFBI 293 7 55.39 6.42e-92 
MGAT4B 34 1 44.59 3.35e-9 
ITGA3 33 1 43.28 7.12e-9 
FSCN1 28 1 36.72 3.02e-7 
SLC16A3 46 2 30.18 3.23e-12 
SEMA4B 20 1 26.22 1.31e-4 
AKT1 20 1 26.22 1.31e-4 
GAPDH 215 11 25.79 4.43e-60 
DDIT4 38 2 24.92 1.61e-9 
SLC25A39 19 1 24.91 2.62e-4 
ESYT1 18 1 23.60 5.36e-4 
MYO1C 17 1 22.28 9.16e-4 
FXYD2 17 1 22.28 9.16e-4 
TNIP1 17 1 22.28 9.16e-4 
HM13 17 1 22.28 9.16e-4 
 
Table 2 demonstrates a list of 17 candidate genes which 
are responsible for renal carcinogenesis, with significant 
low false discovery rate (Q).  With such a low false 
discovery rate, the reliability of the genes is warranted.  The 
chromosomal positions of these genes are given in Table 3. 
 
TABLE 3 
THE CHROMOSOMAL POSITIONS OF THE CANDIDATE GENES 
Genes Chromosomal positions 
IGFBP3 7: 45951955 - 45952627
LMNA 1: 156105877 - 156108962
TGFBI 5: 135364679 - 135399506
MGAT4B 5: 179225009 - 179233625
ITGA3 17: 48140901 - 48143396
FSCN1 7: 5632438 - 5646279
SLC16A3 17: 80186928 - 80197355
SEMA4B 15: 90744573 - 90772890
AKT1 14: 105236679 - 105258980
GAPDH 12: 6643706 - 6647537
DDIT4 10: 74033693 - 74035794
SLC25A39 17: 42396999 - 42400891
ESYT1 12: 56522228 - 56538452
MYO1C 17: 1368124 - 1395951
FXYD2 11: 117690789 - 117695434
TNIP1 5: 150410249 – 150444656
HM13 20: 30154005 - 30154652
Table 3 shows that most of the candidate genes are 
several thousands bases in length.  However, some genes 
are rather short.  IGFBP3 which is located at chromosome 7, 
for example, has only 672 bases.  However, the length of 
genes does not determine the factor for renal carcinogenesis.  
We identified the gene ontology for these 17 genes in order 
to analyze their molecular functions and physiological 
processes.  Gene ontology represents the genome using an 
agreed-upon terms to describe the gene products [3].  Each 
gene could have more than one gene ontology annotations.  
We used a standardized shorthand to represent the type of 
ontology for the 17 candidate genes.  Biological process is 
denoted as [BP], cellular component as [CC], and molecular 
function as [MF].  We demonstrate the gene ontology of the 
top 3 over-expressed genes (IGFBP3, LMNA, and TGFBI) 
in Table 4.   
 
TABLE 4 
GENE ONTOLOGY OF THE TOP 3 OVER-EXPRESSED GENES 
Gene ontology Genes 
[BP]negative regulation of cell 
proliferation
IGFBP3 
[BP]negative regulation of protein 
phosphorylation
IGFBP3 
[BP] negative regulation of signal 
transduction
IGFBP3 
[BP] negative regulation of smooth muscle 
cell migration
IGFBP3 
[BP] negative regulation of smooth muscle 
cell proliferation
IGFBP3 
[BP] positive regulation of apoptosis IGFBP3 
[BP] positive regulation of myoblast 
differentiation 
IGFBP3 
[BP] protein phosphorylation IGFBP3 
[BP] regulation of cell growth IGFBP3 
[CC] extracellular region IGFBP3, TGFBI 
[CC] extracellular space IGFBP3, TGFBI 
[CC] insulin-like growth factor binding 
protein complex 
IGFBP3 
[CC] nucleus IGFBP3 
[MF] insulin-like growth factor I binding IGFBP3 
[MF] insulin-like growth factor binding IGFBP3 
[MF] metal ion binding IGFBP3 
[MF] protein binding IGFBP3, LMNA 
[MF]protein tyrosine phosphatase 
activator activity 
IGFBP3 
[BP] apoptosis LMNA 
[BP] cellular component disassembly 
involved in apoptosis 
LMNA
[BP] establishment or maintenance of 
microtubule cytoskeleton polarity 
LMNA
[BP] muscle organ development LMNA
[BP] nuclear envelope organization LMNA
[BP] positive regulation of cell aging LMNA
[BP] protein localization to nucleus LMNA
[BP] regulation of apoptosis LMNA
[BP] regulation of cell migration LMNA
[BP] spermatogenesis LMNA
[BP] sterol regulatory element binding 
protein import into nucleus 
LMNA




[CC] insoluble fraction LMNA
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[CC] intermediate filament LMNA 
[CC] lamin filament LMNA 
[CC] nuclear envelope LMNA 
[CC] nuclear lamina LMNA 
[CC] nuclear matrix LMNA 
[CC] nucleus LMNA 
[CC] perinuclear region of cytoplasm LMNA 
[MF] structural molecule activity LMNA 
[BP] angiogenesis TGFBI 
[BP] cell proliferation TGFBI 
[BP] extracellular matrix organization TGFBI 
[BP] negative regulation of cell adhesion TGFBI 
[BP] response to stimulus TGFBI 
[BP] visual perception TGFBI 
[CC] extracellular matrix TGFBI 
[CC] proteinaceous extracellular matrix TGFBI 
[MF] extracellular matrix binding TGFBI 
[MF] integrin binding TGFBI 
 
Of these 50 molecular properties (as shown in Table 4) 
which are represented by three main categories of gene 
ontology (BP, CC, MF), we noticed that the top 3 over-
expressed genes (IGFBP3, LMNA, and TGFBI) exemplify a 
wide range of physiological characteristics.  Of 50 
molecular properties, only three properties are shared by 
two genes, which are extracellular region, extracellular 
space, and protein binding.  However, the phenomenon of 
unique gene ontology does not imply the connectionless 
between the genes in renal carcinogenesis.  The more gene 
ontology annotation is attributed to a gene, the more 
physiological role is assumed.  TGBFI has been observed to 
mutate in the renal cells, which contributes to the renal 
carcinogenesis [4].  Experiment has also shown that the 
extracellular matrix protein of TGFBI has a wide 
implication in cancer therapy by inducing chemotherapy 
resistance via apoptosis [5].  It has been an agreement that 
TGFβ, a superfamily of TGFBI, plays a pivotal role in 
cancer progression [6-7].  It was reported that the 
phenotypic spectrum of diseases caused by LMNA 
mutations is diverse [8].  The results of real-time qPCR 
assay showed that the expression level of LMNA was 
significantly increased in a time-dependent manner in 
response to low-intensity pulsed ultrasound in human 
lymphoma U937 cells [9].   IGFBP3 was reported to have 
implicated in the renal cell carcinoma [10] and drug 
tolerance [11].  The results of cDNA microarray 
demonstrated that IGFBP3 assumes a role in cell 
proliferation [12]. 
 
Fig. 1.  Amino acid sequences of the IGFBP3 gene product 
Fig. 1 provides the amino acid sequences of the IGFBP3 
gene product, which shows the characteristic of insulin-like 
growth factor.  
Fig. 2 shows the amino acid sequences of the LMNA 
gene product.  The protein product is prelamin A/C, which 




Fig. 2.  Amino acid sequences of the LMNA gene product 
 
Fig. 3 depicts the amino acid sequences of the TGFBI 





Fig. 3.  Amino acid sequences of the TGFBI gene product 
 
The over-expression of IGFBP3, LMNA, and TGFBI 
explains the respective high sequence odds ratio in renal 
cancer cells.  Gene ontology also supports the observed 
expression of these three genes.  It further validates that 
IGFBP3, LMNA, and TGFBI are important oncogenes that 
account for the renal carcinogenesis.   
IV. CONCLUSIONS 
Practically all genomic data are analysed using 
computational tools and methods. The gene ontology of the 
top 3 over-expressed genes that is IGFBP3, LMNA and 
TGFBI that caused renal cancer are analysed using in silico 
approach in this paper. Factors inducing renal 
carcinogenesis do not depend on the length of genes. The 
gene ontology annotation reflects the physiological roles in 
which mutation in the renal cells contributes to renal 
carcinogenesis.  Examination of amino acid sequences 
indicated that IGFBP3, LMNA and TGFBI all show the 
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characteristic of growth factor. We concluded that IGFBP3, 
LMNA and TGFBI play an important role in renal 
carcinogenesis 
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